Gritstone Bio EBITDA 2017-2024 | GRTSQ
Gritstone Bio ebitda from 2017 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Gritstone Bio Annual EBITDA
(Millions of US $) |
| 2023 |
$-133 |
| 2022 |
$-114 |
| 2021 |
$-68 |
| 2020 |
$-99 |
| 2019 |
$-95 |
| 2018 |
$-62 |
| 2017 |
$-40 |
| 2016 |
$-18 |
Gritstone Bio Quarterly EBITDA
(Millions of US $) |
| 2024-06-30 |
$-26 |
| 2024-03-31 |
$-38 |
| 2023-12-31 |
$-28 |
| 2023-09-30 |
$-37 |
| 2023-06-30 |
$-34 |
| 2023-03-31 |
$-34 |
| 2022-12-31 |
$-31 |
| 2022-09-30 |
$-28 |
| 2022-06-30 |
$-28 |
| 2022-03-31 |
$-27 |
| 2021-12-31 |
$-28 |
| 2021-09-30 |
$-26 |
| 2021-06-30 |
$-23 |
| 2021-03-31 |
$10 |
| 2020-12-31 |
$-25 |
| 2020-09-30 |
$-24 |
| 2020-06-30 |
$-24 |
| 2020-03-31 |
$-25 |
| 2019-12-31 |
$-27 |
| 2019-09-30 |
$-28 |
| 2019-06-30 |
$-22 |
| 2019-03-31 |
$-18 |
| 2018-12-31 |
$-17 |
| 2018-09-30 |
$-18 |
| 2018-06-30 |
$-15 |
| 2018-03-31 |
$-13 |
| 2017-12-31 |
|
| 2017-09-30 |
$-9 |
| 2016-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.016B |
|
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient?s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients? TSNA to drive the patient?s immune system to attack and destroy tumors.
|
